Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REVERT-PREDIABETES
NCT07392151Phase 3Not yet recruiting
- Sponsor
- Michael Mæng
- Start
- Feb 2026
- Primary completion
- Oct 2029
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of semaglutide in prediabetes (3 arms), sponsored by Michael Mæng. Primary endpoints: Presence of a composite of retinopathy, nephropathy, neuropathy, and MASLD and Incidence of normoglycemia defined as HbA1c <39 mmol/mol at 1 year. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
03
Conditions
prediabetes
Beyond the preview
Go deeper on NCT07392151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07392151.